ANTICIPATED NUMBER OF THERAPIES Sample Clauses

ANTICIPATED NUMBER OF THERAPIES. Corixa anticipates being able to provide the number of Therapies set forth below in the Territory in the specified calendar years: Calendar Year Maximum Number of Therapies ------------- --------------------------- [*] [*] [*] [*] -------- * Confidential Treatment Requested. [*] [*] The foregoing estimates are based on assumptions that: (i) the demand for Corixa Iodine I 131 Tositumomab in the Territory will be spread evenly throughout each calendar year and (ii) the percentage of patients requiring a second vial of Corixa Iodine I 131 Tositumomab will not exceed [*]. Amersham acknowledges that if one or both of these assumptions is not correct, then Corixa's ability to provide the anticipated number of Therapies will be adversely affected and the number of available Therapies will be adjusted accordingly. If Corixa becomes able to supply more than the specified number of Therapies in calendar year [*], then the Parties will mutually agree whether Corixa will provide additional Therapies in the Territory. Notwithstanding the foregoing, Amersham acknowledges and agrees that Corixa may be unable to meet the anticipated Therapy requirement for the Territory for a specified week or a specified year even if the amounts of Corixa I 131 Tositumomab ordered by Amersham are in weekly amounts balanced over the applicable calendar year.
AutoNDA by SimpleDocs
ANTICIPATED NUMBER OF THERAPIES. Corixa anticipates being able to provide GSK Canada with up to the number of Therapies set forth below in the specified calendar years: Calendar Year Maximum Number of Therapies ------------- --------------------------- 2003 [*] 2004 [*] 2005 [*] The foregoing estimates are based on the assumption that the percentage of patients requiring a second vial of Iodine I 131 Tositumomab will not exceed [*] If Corixa becomes able to supply more than the specified number of Therapies in any one or more of the calendar years 2003, 2004 or 2005, then Corixa will provide to GSK Canada whatever number of additional Therapies the Parties agree upon. If the Parties fail to agree, then Corixa will provide to GSK Canada [*] of the additional Therapies. GSK Canada shall include ---------------------------------- * Confidential Treatment requested.
ANTICIPATED NUMBER OF THERAPIES. Corixa anticipates being able to provide GSK Canada with up to the number of Therapies set forth below in the specified calendar years: <TABLE> <CAPTION> Calendar Year Maximum Number of Therapies ------------- --------------------------- <S> <C> 2003 [*] 2004 [*] 2005 [*] </TABLE> The foregoing estimates are based on the assumption that the percentage of patients requiring a second vial of Iodine I 131 Tositumomab will not exceed [*] If Corixa becomes able to supply more than the specified number of Therapies in any one or more of the calendar years 2003, 2004 or 2005, then Corixa will provide to GSK Canada whatever number of additional Therapies the Parties agree upon. If the Parties fail to agree, then Corixa will provide to GSK Canada [*] of the additional Therapies. GSK Canada shall include ---------------------------------- * Confidential Treatment requested. 24. <PAGE> such Corixa additional Therapies in the forecasts it supplies pursuant to Sections 4.3(b), 4.3(c) and 4.3(d). (b) SUPPLY FROM BI PHARMA. (i) No later than the [*] day of the [*] month of each [*], GSK Canada shall furnish to Corixa, directly or via SB, a written rolling [*] forecast of GSK Canada's anticipated purchases of Therapies for the Territory which shall be consistent with the terms and conditions of the BI Pharma Agreements (the "BI Pharma Forecast"). The BI Pharma Forecast may be part of the forecast for the same time period that SB provides to Corixa pursuant to the SB Agreement, provided that such forecast is received by Corixa by the date specified in the previous sentence and further provided that the Therapies that GSK Canada intends to purchase will be separately identified in such forecast. Each BI Pharma Forecast shall cover a [*] forecast period starting the [*] day of the [*] after the [*] in which GSK Canada provided such BI Pharma Forecast to Corixa. By way of example, the BI Pharma Forecast which GSK Canada provides by [*] shall cover the period from [*] until [*], and the BI Pharma Forecast which GSK Canada provides by [*] shall cover the period from [*] until [*]. The BI Pharma Forecasts shall be submitted to Corixa in the format agreed upon by the Parties prior to the Effective Date (which format may be amended by Corixa during the term of this Agreement), and shall be consistent with the then-current manufacturing schedule of BI Pharma1. Such forecasts shall not call for supply of more than the maximum number of Therapies stated in Section 4.3(a) for calendar...

Related to ANTICIPATED NUMBER OF THERAPIES

  • Market Capitalization At the time the Registration Statement was or will be originally declared effective, and at the time the Company’s most recent Annual Report on Form 10-K was filed with the Commission, the Company met or will meet the then applicable requirements for the use of Form S-3 under the Securities Act, including, but not limited to, General Instruction I.B.1

  • Authorized Capitalization As of the date of this Agreement, the authorized capitalization of Buyer consists of (i) 1,000,000,000 shares of common stock, par value $0.01 per share, of which 367,735,954 shares are issued and outstanding and (ii) 25,000,000 shares of undesignated preferred stock, par value $0.01 per share, none of which are issued and outstanding. Buyer has no other capital stock authorized, issued or outstanding. There are no outstanding or authorized stock appreciation, phantom stock, profit participation, or similar rights with respect to Buyer. With respect to any Buyer Common Stock that has been issued subject to a right of repurchase on the part of the Company, Disclosure Schedule 4.2(a) sets forth the holder thereof, the number and type of securities covered thereby, and the vesting schedule thereof (including a description of the circumstances under which such vesting schedule can or will be accelerated).

  • Regulatory Capitalization Buyer Bank is, and will be upon consummation of the transactions contemplated by this Agreement, “well-capitalized,” as such term is defined in the rules and regulations promulgated by the FDIC. Buyer is, and will be upon consummation of the transactions contemplated by this Agreement, “well-capitalized” as such term is defined in the rules and regulations promulgated by the FRB.

  • Maximum Leverage Permit, as of any fiscal quarter end, the ratio of (a) Adjusted Portfolio Equity as of such fiscal quarter end to (b) Funded Debt as of such fiscal quarter end, to be less than 5.00 to 1.00.

  • SHARE PRICE The price per Share shall be determined by reference to trades on the Fund’s primary exchange. In no event shall the price be less than the current net asset value per share plus the per share amount of the commission to be paid to you (the “Minimum Price”). You shall suspend the sale of Shares if the per share price of the Shares is less than the Minimum Price.

  • Black-Out Periods (a) Notwithstanding Section 2, and subject to the provisions of this Section 3, the Company shall be permitted, in limited circumstances, to suspend the use, from time to time, of the Prospectus that is part of a Shelf Registration Statement (and therefore suspend sales of the Registrable Securities under such Shelf Registration Statement), by providing written notice (a “Suspension Notice”) to the Selling Holders’ Counsel, if any, and the Holders, for such times as the Company reasonably may determine is necessary and advisable (but in no event for more than an aggregate of ninety (90) days in any rolling twelve (12)-month period commencing on the date of this Agreement or more than forty-five (45) consecutive days, except as a result of a refusal by the Commission to declare any post-effective amendment to the Shelf Registration Statement effective after the Company has used all reasonable best efforts to cause the post-effective amendment to be declared effective by the Commission, in which case, the Company must terminate the black-out period immediately following the effective date of the post-effective amendment) if either of the following events shall occur: (i) a majority of the Board determines in good faith that (A) the offer or sale of any Registrable Securities would materially impede, delay or interfere with any proposed financing, offer or sale of securities, acquisition, corporate reorganization or other material transaction involving the Company, (B) after the advice of counsel, the sale of Registrable Securities pursuant to the Shelf Registration Statement would require disclosure of non-public material information not otherwise required to be disclosed under applicable law, and (C) (x) the Company has a bona fide business purpose for preserving the confidentiality of such transaction, (y) disclosure would have a material adverse effect on the Company or the Company’s ability to consummate such transaction, or (z) such transaction renders the Company unable to comply with Commission requirements, in each case under circumstances that would make it impractical or inadvisable to cause the Shelf Registration Statement (or such filings) to become effective or to promptly amend or supplement the Shelf Registration Statement on a post-effective basis, as applicable; or (ii) a majority of the Board determines in good faith, upon the advice of counsel, that it is in the Company’s best interest or it is required by law, rule or regulation to supplement the Shelf Registration Statement or file a post-effective amendment to the Shelf Registration Statement in order to ensure that the Prospectus included in the Shelf Registration Statement (1) contains the information required under Section 10(a)(3) of the Securities Act; (2) discloses any facts or events arising after the effective date of the Shelf Registration Statement (or of the most recent post-effective amendment) that, individually or in the aggregate, represents a fundamental change in the information set forth therein; or (3) discloses any material information with respect to the plan of distribution that was not disclosed in the Shelf Registration Statement or any material change to such information. Upon the occurrence of any such suspension, the Company shall use its reasonable best efforts to cause the Shelf Registration Statement to become effective or to promptly amend or supplement the Shelf Registration Statement on a post-effective basis or to take such action as is necessary to make resumed use of the Shelf Registration Statement as soon as possible.

  • Number of Units The Participant is granted the number of RSUs as specified in the Participant’s account under the 0000 XXX grant, administered by Fidelity Investments or any successor thereto (“Fidelity”). A RSU is a hypothetical share of Verizon’s common stock. The value of a RSU on any given date shall be equal to the closing price of Verizon’s common stock on the New York Stock Exchange (“NYSE”) as of such date. A Dividend Equivalent Unit (“DEU”) or fraction thereof shall be added to each RSU each time that a dividend is paid on Verizon’s common stock. The amount of each DEU shall be equal to the corresponding dividend paid on a share of Verizon’s common stock. The DEU shall be converted into RSUs or fractions thereof based upon the closing price of Verizon’s common stock traded on the NYSE on the dividend payment date of each declared dividend on Verizon’s common stock, and such RSUs or fractions thereof shall be added to the Participant’s RSU balance. To the extent that Fidelity or the Company makes an error, including but not limited to an administrative error with respect to the number or value of the RSUs granted to the Participant under this Agreement, the DEUs credited to the Participant’s account or the amount of the final award payment, the Company or Fidelity specifically reserves the right to correct such error at any time and the Participant agrees that he or she shall be legally bound by any corrective action taken by the Company or Fidelity.

  • Black-Out Period (a) Subject to the provisions of this Section 6 and a good faith determination by the Company that it is in the best interests of the Company to suspend the use of a Registration Statement, following the effectiveness of such Registration Statement (and the filings with any international, federal or state securities commissions), the Company, by written notice to Stifel and the Holders, may direct the Holders to suspend sales of the Registrable Shares pursuant to such Registration Statement for such times as the Company reasonably may determine is necessary and advisable (but in no event for more than an aggregate of ninety (90) days in any rolling twelve (12)-month period commencing on the Closing Date or more than sixty (60) days in any rolling ninety (90)-day period), if any of the following events shall occur: (i) the representative(s) of the underwriter(s) of an Underwritten Offering of primary shares by the Company has advised the Company that the sale of Registrable Shares pursuant to the Registration Statement would have a material adverse effect on the Company’s primary Underwritten Offering; (ii) the Company shall have determined in good faith that (A) the offer or sale of any Registrable Shares would materially impede, delay or interfere with any proposed financing, offer or sale of securities, acquisition, merger, tender offer, business combination, corporate reorganization or other significant transaction involving the Company, (B) after the advice of counsel, the sale of Registrable Shares pursuant to the Registration Statement would require disclosure of non-public material information not otherwise required to be disclosed under applicable law and (C) (1) the Company has a bona fide business purpose for preserving the confidentiality of such transaction, (2) disclosure would have a material adverse effect on the Company or the Company’s ability to consummate such transaction or (3) renders the Company unable to comply with Commission requirements, in each case under circumstances that would make it impractical or inadvisable to cause the Registration Statement (or such filings) to become effective or to promptly amend or supplement the Registration Statement on a post-effective basis, as applicable; or (iii) the Company shall have determined in good faith, after the advice of counsel, that it is required by law, rule or regulation or that it is in the best interests of the Company to supplement the Registration Statement or file a post-effective amendment to the Registration Statement in order to incorporate information into the Registration Statement for the purpose of (A) including in the Registration Statement any prospectus required under Section 10(a)(3) of the Securities Act; (B) reflecting in the Prospectus included in the Registration Statement any facts or events arising after the effective date of the Registration Statement (or of the most recent post-effective amendment) that, individually or in the aggregate, represent a fundamental change in the information set forth therein; or (C) including in the Prospectus included in the Registration Statement any material information with respect to the plan of distribution not disclosed in the Registration Statement or any material change to such information. Upon the occurrence of any such suspension, the Company shall use its best efforts to cause the Registration Statement to become effective or to promptly amend or supplement the Registration Statement on a post-effective basis or to take such action as is necessary to make resumed use of the Registration Statement compatible with the Company’s best interests, as applicable, so as to permit the Holders to resume sales of the Registrable Shares as soon as possible.

  • Organization; Capitalization Borrower is a corporation duly organized, validly existing and in good standing under the laws of the state of California and has all requisite corporate power and authority to own its property and to carry on its business as now being conducted.

  • EBITDA With respect to REIT and its Subsidiaries for any period (without duplication): (a) Net Income (or Loss) on a Consolidated basis, in accordance with GAAP, exclusive of the following (but only to the extent included in determination of such Net Income (Loss)): (i) depreciation and amortization expense; (ii) Interest Expense; (iii) income tax expense; (iv) Acquisition Closing Costs and extraordinary or non-recurring gains and losses (including, without limitation, gains and losses on the sale of assets) and income and expense allocated to minority owners; and (v) other non-cash items to the extent not actually paid as a cash expense; plus (b) such Person’s pro rata share of EBITDA of its Unconsolidated Affiliates as provided below. With respect to Unconsolidated Affiliates and Subsidiaries of Borrower that are not Wholly Owned Subsidiaries, EBITDA attributable to such entities shall be excluded but EBITDA shall include a Person’s Equity Percentage of Net Income (or Loss) from such Unconsolidated Affiliates or such Subsidiary of Borrower that is not a Wholly Owned Subsidiary plus its Equity Percentage of (i) depreciation and amortization expense; (ii) Interest Expense; (iii) income tax expense; (iv) Acquisition Closing Costs and extraordinary or non-recurring gains and losses (including, without limitation, gains and losses on the sale of assets) and income and expense allocated to minority owners; and (v) other non-cash items to the extent not actually paid as a cash expense.

Time is Money Join Law Insider Premium to draft better contracts faster.